<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509469</url>
  </required_header>
  <id_info>
    <org_study_id>NL36916.068.11</org_study_id>
    <nct_id>NCT01509469</nct_id>
  </id_info>
  <brief_title>The Effect of Different Macronutrients on Ileal Brake Activation</brief_title>
  <official_title>The Effect of Different Macronutrients on Ileal Brake Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Top Institute Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ileal infusion of casein and sucrose can&#xD;
      activate the ileal brake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The appearance of a food matrix into the duodenum, both during a meal and during the&#xD;
      postprandial phase results in a feed-back from different parts of the intestine to the&#xD;
      stomach, to the small intestine and to the central nervous system. All these processes&#xD;
      inhibit, in concert, food processing in the gastrointestinal tract, satiation and appetite&#xD;
      sensations and, consequently, food intake. These processes are involved in the so-called&#xD;
      intestinal brake. The location at which the feedback process is initiated determines the&#xD;
      severity of the brake effect; the entry of nutrients into the duodenum and jejunum activates&#xD;
      the so-called duodenal and jejunal &quot;brakes&quot;: negative feedback mechanisms that influence the&#xD;
      function of more proximal parts of the gastrointestinal tract. Activation of both of these&#xD;
      feedback mechanisms results in reduction of food intake and inhibition of hunger, probably&#xD;
      partly by inhibition of gastric emptying rate (thus contributing to enhanced and prolonged&#xD;
      gastric distension) and small intestinal transit time. More distal in the small intestine,&#xD;
      the ileal brake is a feedback mechanism that results in inhibition of proximal&#xD;
      gastrointestinal motility and secretion and increase feelings of satiation and reduction of&#xD;
      ad libitum food intake.These results all point to a potentially powerful role of the ileal&#xD;
      brake in the regulation of digestion, with direct or indirect impact upon eating behaviour&#xD;
      and satiation.&#xD;
&#xD;
      The current scientific data strongly suggest that activation of the ileal brake provides the&#xD;
      most powerful feedback mechanism to gastrointestinal transit and, especially, satiety signals&#xD;
      and food intake. Most studies have used fat as macronutrient. The effects of several amounts,&#xD;
      types and preparations of fat on the ileal brake have previously been investigated and&#xD;
      reported.&#xD;
&#xD;
      Until present, the effects of the other macronutrients to induce the ileal brake remain&#xD;
      largely unknown. There is evidence that carbohydrates induce the ileal brake. Proteins may&#xD;
      also exert effects, although data are scarce and not convincing. However, it becomes more and&#xD;
      more accepted that proteins may induce stronger effects on satiation and food intake than fat&#xD;
      or carbohydrates.&#xD;
&#xD;
      In this study we're going to investigate the effect of intraileal infusion of casein and&#xD;
      sucrose on ileal brake activation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in satiation (as measured by VAS) and food intake as measured during an ad libitum meal</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone Cholecystokinin (CCK)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying by using the C13 stable isotope breath test</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small bowel transit time by using lactulose hydrogen breath test</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gallbladder volumes by gallbladder ultrasound</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone Glucagon Like Peptide-1 (GLP-1)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements in plasma and/or platelet poor plasma Plasma levels of the gut hormone peptide YY (PYY)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Low dose casein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ileal infusion of low dose casein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose casein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ileal infusion of high dose casein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose sucrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ileal infusion of low dose sucrose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose sucrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ileal infusion of high dose sucrose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ileal infusion saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safflower oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ileal infusion safflower oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Casein</intervention_name>
    <description>Ileal infusion of low dose casein (5 gram)</description>
    <arm_group_label>Low dose casein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Casein</intervention_name>
    <description>Ileal infusion of high dose casein (15 gram)</description>
    <arm_group_label>High dose casein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucrose</intervention_name>
    <description>Ileal infusion of low dose sucrose (4.3 gram)</description>
    <arm_group_label>Low dose sucrose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucrose</intervention_name>
    <description>Ileal infusion of high dose sucrose (12.9 gram)</description>
    <arm_group_label>High dose sucrose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Ileal infusion with saline (180mL in total)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Safflower oil</intervention_name>
    <description>Ileal infusion with safflower oil (6gr safflower oil in water)</description>
    <arm_group_label>Safflower oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Based on medical history and previous examination, no gastrointestinal complaints can&#xD;
             be defined.&#xD;
&#xD;
          -  Age between 18 and 55 years. This study will include healthy adult subjects (Male and&#xD;
             Female), Women must be taking oral contraceptives. Subjects over 55 years have an&#xD;
             increased risk for comorbidities, therefore, subjects over 55 years will not be&#xD;
             included.&#xD;
&#xD;
          -  BMI between 18 and 29 kg/m2&#xD;
&#xD;
          -  Less then 2 'yes' responses in the SCOFF questionnaire (see appendix F1)&#xD;
&#xD;
          -  Weight stable over at least the last 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic,&#xD;
             hematological/immunologic, HEENT (head, ears, eyes, nose, throat),&#xD;
             dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,&#xD;
             neurological/psychiatric diseases, allergy, major surgery and/or laboratory&#xD;
             assessments which might limit participation in or completion of the study protocol.&#xD;
             The severity of the disease (major interference with the execution of the experiment&#xD;
             or potential influence on the study outcomes) will be decided by the principal&#xD;
             investigator.&#xD;
&#xD;
          -  Use of medication, including vitamin supplementation, except oral contraceptives,&#xD;
             within 14 days prior to testing&#xD;
&#xD;
          -  Administration of investigational drugs or participation in any scientific&#xD;
             intervention study which may interfere with this study (to be decided by the principle&#xD;
             investigator), in the 180 days prior to the study&#xD;
&#xD;
          -  Major abdominal surgery interfering with gastrointestinal function (uncomplicated&#xD;
             appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon&#xD;
             judgement of the principle investigator)&#xD;
&#xD;
          -  Dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological&#xD;
             dynamic)&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Excessive alcohol consumption (&gt;20 alcoholic consumptions per week)&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Blood donation within 3 months before the study period&#xD;
&#xD;
          -  Self-admitted HIV-positive state&#xD;
&#xD;
          -  Eating disorders detected using the 'SCOFF questionnaire' (in Dutch translation)&#xD;
&#xD;
          -  Lactose or cow milk intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Masclee, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre +</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2012</study_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Mark van Avesaat</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Ileal brake</keyword>
  <keyword>Casein</keyword>
  <keyword>Sucrose</keyword>
  <keyword>Ileal infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caseins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

